Pharvaris N.V. (PHVS)
15.40
-0.40 (-2.53%)
At close: Mar 31, 2025, 3:59 PM
15.69
1.85%
Pre-market: Apr 01, 2025, 04:27 AM EDT
-2.53% (1D)
| Bid | 14.42 |
| Market Cap | 831.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -132.99M |
| EPS (ttm) | -2.79 |
| PE Ratio (ttm) | -5.52 |
| Forward PE | -5.9 |
| Analyst | Buy |
| Ask | 16.95 |
| Volume | 21,457 |
| Avg. Volume (20D) | 44,523 |
| Open | 15.82 |
| Previous Close | 15.80 |
| Day's Range | 15.21 - 15.82 |
| 52-Week Range | 14.14 - 25.50 |
| Beta | -3.02 |
About PHVS
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 92
Stock Exchange NASDAQ
Ticker Symbol PHVS
Website https://pharvaris.com
Analyst Forecast
According to 6 analyst ratings, the average rating for PHVS stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 185.71% from the latest price.
Stock Forecasts
